Federal Jury Orders Gilead To Pay Merck $200 Million In Hepa C Drug Patent Dispute Merck is set to receive $200 million in damages from Gilead Sciences as federal jury decides on patent dispute. Merck claims they should be credited for liver therapy breakthrough. by Catherine Cabral-Isabedra
Healthy Living/Wellness Intarcia Diabetes Implant Shows Promising Results During Phase 3 Trials by Ted Ranosa